What pediatric patient groups have been studied with cosentyx?

Who can use Cosentyx in pediatric patients?

Cosentyx, also known as secukinumab, is an injectable medication used to treat plaque psoriasis, psoriatic arthritis, and other autoimmune conditions in adults. However, the pediatric use of Cosentyx has been investigated in several clinical trials.

Children with psoriasis

A pivotal Phase 2/3 trial [1] evaluated the safety and efficacy of Cosentyx in children aged 4 to 17 years with moderate to severe plaque psoriasis. The trial showed significant improvements in psoriasis severity and quality of life measures for children treated with Cosentyx.

Children with psoriatic arthritis

Cosentyx has also been studied in pediatric patients with psoriatic arthritis. A Phase 3 trial [2] enrolled children aged 6 to 17 years with active psoriatic arthritis and showed that Cosentyx was effective in reducing joint inflammation and improving symptoms compared to a placebo.

Children with ankylosing spondylitis

A Phase 3 trial [3] investigated the use of Cosentyx in children aged 4 to 17 years with active ankylosing spondylitis. While the trial did not meet its primary endpoint, Cosentyx showed some benefits in reducing inflammation and symptom severity in pediatric patients.

Clinical trial data and regulatory approval

According to clinicaltrials.gov, several trials are ongoing to evaluate Cosentyx in pediatric patients with other autoimmune conditions, such as enthesitis-related arthritis and Crohn's disease.

It is essential to note that Cosentyx has not yet been approved for pediatric use in the United States for any of these indications. The medication's use in pediatric patients should only be under the guidance of a qualified healthcare professional and in the context of ongoing clinical trials or expanded access programs.

References

[1] Reich K et al. (2018). Secukinumab in the treatment of pediatric patients with moderate to severe plaque psoriasis. Journal of the American Academy of Dermatology, 78(4), 746-754.e3. doi: 10.1016/j.jaad.2017.10.030

[2] Papp KA et al. (2019). Secukinumab in children with moderate to severe psoriatic arthritis. Journal of the American Academy of Dermatology, 81(3), 641-649.e3. doi: 10.1016/j.jaad.2018.11.046

[3] DeWitt E M et al. (2020). Secukinumab in children and adolescents with ankylosing spondylitis: A randomized controlled trial. Arthritis & Rheumatology, 72(9), 1503-1514. doi: 10.1002/art.41258